Evidence Table E62. Binge eating disorder drug treatment – part 8

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Arnold, 200266 | Weight (kg) (M,SD)BMI (M,SD) | Weight, kg, mean (SD):G1: 110.4 (24.1)G2: 103.5 (19.0)(P = NS)BMI, kg/m², mean(SD):G1: 39.6 (7.0)G2: 36.7 (6.8)(P = NS) | Weight, kg, mean (SE):G1: 112.5 (25.0)G2: 110.3 (18.2)Diff between groups (P = NR)Diff between groups in change over time (time trend analysis, P = 0.001; endpoint analysis, P < 0.0001), G1 better than G2BMI, kg/m², mean (SD):G1: 40.0 (7.2)G2: 39.5 (6.3)Diff between groups (P = NR)Diff between groups in change over time (time trend analysis, P < 0.0001; endpoint analysis, P < 0.0001), G1 better than G2 | NA | NA | NA |

Evidence Table E62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Brownley, 201367 | Weight (kg) | Weight (kg):BaselineG1: 99.9 (21.8)G2: 96.3 (26.8)G3: 100.0 (16.1)p = 0.93 | Weight (kg):Monthly rate of changeG1: 0.19 (0.25)G2: -0.13 (0.23)G3: 0.55 (0.25)p = ns | Fasting gluclose (mg/dL)Glycated hemoglobin (HbA1c %) | Fasting glucose (mg/dL):baselineG1: 90.6 (10.0)G2: 92.8 (13.8)G3: 91.4 (8.4)p = 0.99HbA1c:baselineG1: 5.5 (0.3)G2: 5.7 (0.5)G3: 5.5 (0.4)p = 0.99Overall: 5.6 (0.4) | Fasting glucose (mg/dL):Monthly rate of changeG1: -1.08 (0.80)G2: -0.67 (0.74)G3: 2.53 (0.80)G1 v G3t: -3.19df: 35p < 0.01G2 v G3t: -2.93df: 35p <0.01HbA1c:6 monthsoverall: 5. 6 (0.4) |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Guerdjikova, 200968 | Weight (kg)Body Mass Index | Weight,kg (M,SD)G1: 105.93 (19.08)G2: 120 (25.39)BMI (M, SD)G1: 38.72 (5.38)G2: 41.52 (7.24) | Weight,kg (M,SD)G1: 104.55 (19.30)G2: 119.95 (25.86)Diff between groups (p = 0.166) Diff between groups in change over time (p =0.207)Weight loss, kg (M, SD)G1: 1.17 (2.96)G2: 0.15 (3.61)p=NSBMI (M,SD)G1: 38.24 (5.70)G2: 41.50 (7.42)Diff between groups (p =0.189) Diff between groups in change over time (p =0.236) | Glucose (mg/dl)Insulin (mmU/ml)Total cholestrol (mg/dl)HDL (mg/dl)LDL (mg/dl)Triglycerides (mg/dl)Leptin (ng/ml)Ghrelin (ng/dl) | Glucose (mg/dl) (M,SD for this & all variables below)G1: 97.88 (39.30)G2: 84.42 (13.58)Insulin (mmU/ml)G1: 12.80 (9.08)G2: 12.38 (5.94)Total cholestrol (mg/dl)G1: 200.25 (48.20)G2: 195.23 (46.85)HDL (mg/dl)G1: 58.54 (16.33)G2: 51.63 (11.42)LDL (mg/dl)G1: 155.33 (212.04)G2: 120.54 (21.58)Triglycerides (mg/dl)G1: 144.46 (69.92)G2: 154.58 (67.44)Leptin (ng/ml)G1: 39.49 (21.41)G2: 42.00 (29.39)Ghrelin (ng/dl)G1: 722.61 (187.28)G2: 704.00 (260.07) | Glucose (mg/dl) (M,SD)G1: 87.60 (16.61)G2: 90.29 (8.20)p=0.027 (endpoint analysis for this variable and all below)Insulin (mmU/ml) (M,SD)G1: 11.64 (9.14)G2: 13.26 (7.26)p=0.010Total cholestrol (mg/dl) (M,SD)G1: 185.07 (38.43)G2: 200.00 (29.12)p=0.177HDL (mg/dl) (M,SD)G1: 58.54 (16.33)G2: 51.63 (11.42)p=0.493LDL (mg/dl) (M,SD)G1: 104.87 (33.17)G2: 117.94 (27.2)p=0.809Triglycerides (mg/dl) (M,SD)G1: 124.73 (67.31)G2: 161.06 (77.54)p=0.015Leptin (ng/l) (M,SD)G1: 33.09 (23.26)G2: 38.97 (27.05)p=0.220Ghrelin (ng/l) (M,SD)G1: 753.21 (208.59)G2: 695.40 (234.25)p=0.350 |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Guerdjikova, 200869 | Weight (kg)BMI (kg/m2) | Weight (kg), M(SD)G1: 113.0 (20.0)G2: 109.2 (17.2)p=NSBMI (kg/m2), M(SD)G1: 40.1 (6.8)G2: 40.3 (4.8)p=NS | Weight (kg), M (SD)G1: 112.0 (20.0)G2: 109.8 (17.8)Time-trend analysisEstimate between-group difference in 12-week change (95% CI): 2.1 (0.8, -3.4)chi-square: 8.41p=0.002Endpoint analysisEstimate between-group difference in change from BL to final visit (95% CI): 1.7 (0.1, -3.2)t=3.14p=0.037Completers analysis change in weight from BL to 12wkG1: -1.1 (2.9) kgG2: 0.7 (2.5) kgp=0.037BMI (kg/m2), M(SD) G1: 40.4 (7.0)G2:40.5 (5.0)Time-trend analysisEstimate between-group difference in 12-week change (95% CI): 0.7 (0.3, -1.2)chi-square: 8p=0.003 | Fasting measures of-insulin-glucose-triglycerides-LDL cholesterol-total cholesterol-leptin-ghrelin | Insulin , µU/mL, M (SD)G1: NRG2: NRp=NSGlucose, mg/dL, M (SD)G1: NRG2: NRp=NSTriglycerides, mg/dL, M (SD)G1: NRG2: NRp=NSLDL cholesterol, mg/dL, M (SD)G1: NRG2: NRp=NSTotal cholesterol, mg/dL, M (SD)G1: NRG2: NRp=NSLeptin, ng/mL, M (SD)G1: 43.1 (SD 16.1)G2: 42.9 (SD 18.3)p=NSGhrelin, ng/L, M (SD)G1: 818.6 (SD 369.5)G2: 821.9 (SD 343.8)p=NS | Insulin mean change from BL to final visit, µU/mLG1: -0.2G2: 2.3p=NSGlucose mean change from BL to final visit, mg/dLG1: -0.3G2: -2.3p=NSTriglycerides mean change from BL to final visit, mg/dLG1: -6.6G2: 3.1p=NSLDL cholesterol mean change from BL to final visit, mg/dLG1: 2.8G2: 7.6p=NSTotal cholesterol mean change from BL to final visit, mg/dLG1: 4.8G2: 10.5p=NS |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Guerdjikova, 200869(continued) |  |  | Endpoint analysisEstimate between-group difference in change from BL to final visit (95% CI): 0.6 (0.0, -1.1)t= 2.03p=0.048 |  |  | Leptin mean change from BL to final visit, ng/mLG1: 0.1G2: 2.9p=NSGhrelin mean change from BL to final visit, ng/LG1: -1.6G2: 71.8p=NS |
| Guerdjikova, 201270 | Weight (kg)BMI (kg/m2) | Weight (kg)G1: 111.1 (24.1)G2: 118.3 (23.1)p = NRBMI (kg/m2)G1: 38.7 (6.8)G2: 42.8 (7.6)p = NR | Weight (kg)G1: 108.3 (23.8)G2: 118.0 (23.2)Longitudinal Analysisd = 0.66p = 0.04Endpoint Analysisd = 0.59p = 0.07BMI (kg/m2)G1: 37.7 (7.5)G2: 42.9 (7.3)Longitudinal Analysisd = 0.53p = 0.11Endpoint Analysisd = 0.58p = 0.08 | NA | NA | NA |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Hudson, 199871 | Body Mass Index (BMI) | BMI, kg/m², M (SD)G1: 34.2 ( 6.0)G2: 36.8 (SD 8.2) | BMI, kg/m², M (SD)Treatment-by-time interaction:-0.167 (SE 0.083)p=0.04 | NA | NA | NA |
| Leombruni, 200872 | Weight (kg)Body Mass Index (BMI) | WeightG1: 101.9 (12.5)G2: 99.6 (14.5)BMIG1: 40.2 (3.9)G2: 38.6 (3.8) | WeightT8G1: 98.3 (12.6)G2: 96.1 (16.3)T12G1: 97.4 (13.6)G2: 95.5 (17.5)T24G1: 98.6 (14.8)G2: 94.7 (17.8)time effect p<0.002time x group effect p<0.576BMIT8G1: 38.8 (3.9)G2: 37.2 (3.9)T12G1: 38.4 (4.2)G2: 36.9 (4.1)T24G1: 38.5 (5.0)G2: 36.6 (4.3)time effect p<0.001time x group effect p<0.569 | NA | NA | NA |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200773 | Weight, kgBody Mass Index (BMI) | Weight, mean (SD):G1: 106.9 (20.2)G2: 116.6 (30.1)BMI, mean (SD):G1: 37.3 (6.7)G2: 41.4 (8.5) | WeightLongitudinal AnalysisEstimate (mean change btwn g1 - g2): -3.0995% CI: -5.46 to -0.72X^2: 6.61p: 0.10Endpoint AnalysisEstimate (mean change btwn g1-g)2: -2.6995% CI: -4.88 to 0.49t: 2.48p: 0.018BMILongitudinal AnalysisEstimate (mean change btwn g1 - g2): -1.0395% CI: -1.86 to -0.20X^2: 5.93p: 0.016Endpoint AnalysisEstimate (mean change btwn g1-g)2: -0.8995% CI: -1.66 to 0.12t: 2.34p: 0.025 | NR | NR | NR |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200674 | Weight (kg)Body mass index (BMI) | Weight (kg), mean (SD):G1: 118.0 (SD 30.7)G2: 112.8 (SD 24.3)p=NR, NSBMI, mean (SD):G1: 42.7 (SD 9.5)G2: 40.6 (SD 7.6)p=NR, NS | Weight (kg)Longitudinal analysis G1: NRG2: NRMean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -2.86 (95% CI -4.57 to -1.14)p<0.001Endpoint analysisG1: NRG2: NRMean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): -3.68 (95% CI -5.91 to -1.45)p=0.002BMI | Leptin, ng/mLGhrelin, ng/LGlucose, mg/dLinsulin microUnits/mLtriglycerides, mg/dLLDL cholesterol, mg/dLtotal cholesterol, mg/dL | Leptin, ng/mL, mean (SD)G1: 29.1 (SD 9.7)G2: 27.1 (SD 7.8)p=NR, NSGhrelin, ng/L, mean (SD):G1: 995.7 (SD 216.0)G2: 934.7 (SD 212.0)p=NR, NSGlucose, insulin, triglycerides, LDL cholesterol, total cholesterol, all = NR | Ghrelin change from baseline, mean:G1: 98.6G2: -156.8t=4.0, p=0.001Leptin change from baseline, mean:G1: -5.1G2: -1.1p=NR, NSInsulin change from baseline, mean:G1: 15.7G2: 8.4p=NR, NSGlucose change from baseline, mean:G1: 0.4G2: -1.1p=NR, NSTriglycerides change from baseline, mean:G1: -4.5G2: -12.2p=NR, NSLDL cholesterol change from baseline, mean:G1: 7.2G2: 2.9p=NR, NS |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200674(continued) |  |  | Longitudinal analysisG1: NRG2: NRMean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -1.02 (95% CI -1.64 to -0.41)p=0.001Endpoint analysisG1: NRG2: NRMean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): -1.32 (95% CI -2.07 to -0.56)p<0.001 |  |  | Total cholesterol change from baseline, mean:G1: 8.5G2: -5.4p=NR, NS |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200375 | Body Mass Index (BMI)Weight | BMI, kg/m2, mean (SD)G1: 41.4 (6.9)G2: 34.2 (7.4)p = 0.003Weight, kg, mean (SD)G1: 116.8 (21.0)G2: 94.6 (23.2)p = 0.004 | BMI, kg/m2, mean (SD)G1: 40.9 (7.0)G2: 35.7 (7.5)Time Trend Analysis:Mean difference between groups in rate of change: -0.525 (SE 0.145)p < 0.001Endpoint Analysis:Mean difference between groups in change from BL to 6wk: -0.818 (SE 0.254)p = 0 .001Weight (kg), mean (SD)G1: 114.1 (22.4)G2: 99.8 (24.7)Time Trend Analysis:Mean difference between groups in rate of change: -1.43 (SE 0.40)p < 0.001Endpoint Analysis:Mean difference between groups in change from BL to 6wk: -2.49 (SE 0.66)p < 0.001 | NA | NA | NA |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200376 | Body mas index (BMI)Weight (kg)Body Fat, % | Weight, mean (SD)G1: 120.4 (18.3)G2: 123.4 (24.4)BMI, mean (SD)G1: 44.2 (7.1)G2: 42.0 (6.7) (note, error in manuscript table 1, BMI = 2.0)Body fat = NR | BMIG1: NRG2: NRDiff between groups, p = NRDiff between groups in rate of change, p = 0.003Greater improvements for G1Weight loss kg, meanG1: 5.9G2: 1.2Diff between groups, p = NRDiff between groups in rate of change, p = 0.005Body FatPercent, p = 0.005Total, p = 0.001 Greater improvements for G1 | Diastolic blood pressureInsulin (mmu/ml)Glucose (mg/dl)Cholesterol (mg/dl)Triglycerides (mg/dl) Total cholesterol (mg/dl) | NR | Diastolic blood pressure change, mmHg, mean:G1: -2.71G2: 0.47p = 0.04All other measures, p = NSInsulin change, microunits/mL), mean:G1: -5.78 G2: -0.76Glucose change, mg/dL, mean:G1: -2.4G2: 0.82LDL Cholesterol change, mg/dL, mean:G1: -8.40G2: -0.44Triglyceride change, mg/dL, mean:G1: -27.2G2: -8.06Total cholesterol change, mg/dL, mean:G1: -17.13G2: -2.13 |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200077 | Body mass index (BMI), kg/m2 | BMI, mean (SD):G1: 36.4 (7.4)G2: 35.8 (7.5) | BMI, mean (SD): Diff in change between G1 & G2, mean: -0.596SE: 0.189p = 0.002G1 better than G2 | NR | NR | NR |
| McElroy, 201178 | Weight, kgBody mass index (BMI), kg/m2 | Weight, mean (SD):G1: 116.5 (27.3)G2: 107.7 (23.7)p = 0.28BMI, mean (SD):G1: 39.8 (7.5)G2: 39.2 (8.4)p = 0.71 | Longitudinal Analysis:Weight, mean (SD):G1: 116.3 (27.6)G2: 108.9 (24.3)p = 0.44BMI, mean (SD):G1: 39.7 (7.4)G2: 39.7 (8.9)p = 0.32Endpoint Analysis:Weight, mean (SD):p = 0.40BMI, mean (SD):p = 0.35 | NA | NA | Mean change from baseline to final visitAll p = NR, stated NSInsulin, microInternationalUnits/mLG1: 3.7 G2: 0Glucose, mg/dLG1: 0 G2: 0Triglycerides, mg/dLG1: 9.8 G2: 10.4LDL cholesterol, mg/dLG1: 0.1G2: 0.4Total cholesterol, mg/dLG1: 1.3 G2:1.0 |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200779 | Weight, kgBody mass index (BMI), kg/m2 | Weight, kg, ean (SD)G1: 106 (18.5)G2: 107 (18.3)BMI, mean (SD)G1: 38 (5.1)G2: 39 (5.5) | Longitudinal Analysis, rate of changeWeightG1 better than G2, rate of reductionp < 0.001BMIG1 better than G2, rate of reductionp < 0.001 | NA | NA | NA |
| McElroy, 201380 | Weight (kg)Body mass index (BMI), kg/m2Waist circumference (cm) | Weight (kg), mean (SD)G1: 106.0 (13.5)G2: 107.6 (17.7)p=0.70BMI, mean (SD)G1: 38.6 (4.8)G2: 39.2 (6.4)p=0.69Waist circumference (cm), mean (SD)G1: 114.1 (9.9)G2: 115.2 (12.1)p=0.70 | Weight (kg), mean change (SD) from baseline to endpointG1: -0.03 (2.02)G2: -0.23 (3.16)p=0.76BMI, mean change (SD) from baseline to endpointG1: 0.01 (0.69)G2: -0.07 (1.27)p=0.75Waist circumference (cm), mean change (SD) from baseline to endpointG1: -0.95 (4.14)G2: -0.57 (3.54)p=0.74 | NA | NA | NA |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 201581 | Weight (kg) | Weight (kg)G1: 98.5 (SD 18.65)G2: 100.6 (SD 18.84)G3: 98.4 (SD 16.70)G4: 96.8 (SD 17.28) | 11wk Mean change in body weightG1: -3.1 (SD 3.64)G2: -4.9 (SD 4.43)G3: -4.9 (SD 3.93)G4: -0.1 (SD 3.09)11wk Mean % reduction in body weight, difference from placebo, LS change, mean (SE)G1: 3.268% (SE 0.7197%)G2: 5.179% (SE 0.7214%)G3: 5.282% (SE 0.7229%)G4: N/A11wk Mean change in body weight: Significant difference compared with placeboG1 p<0.001G2 p<0.001G3 p<0.001G4 N/A | None | None | None |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Pearlstein, 200382 | Weight (lbs) | Weight, lbs (M, SD)G1: 243 (85)G2: 258 (96)(P = NS) | Weight, lbs (M, SD)G1: 242 (82)G2: 262 (99)Diff between groups (P = NR)Change over time for both groups: (P = NS)Diff between groups in change over time (P = NS) | NA | NA | NA |
| Shire, 201483,84 | Body weight | LBSG1: 208.9G2: 205.3 KGG1: 94.8G2: 93.1 | Change in body weightG1: -5.57% (0.350)G2: -0.15% (0.353)Mean diff: -5.41 (-6.39 to -4.44)(p < 0.001) | NA | NA | NA |
| Shire, 201484,85 | Body weight | LBSG1: 208.9G2: 205.3 KGG1: 94.8G2: 93.1 | Change in body weightG1: -5.57% (0.350)G2: -0.15% (0.353)Mean diff: -5.41 (-6.39 to -4.44)(p < 0.001) | NA | NA | NA |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last NameYear | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| White, 201386 | BMIWeight | BMIG1: 36.2 (SD 6.6)G2: 35.4 (SD 7.1)WeightG1: NRG2: NR | 8wkG1: 35.7 (SD 6.6)G2: 35.2 (SD 7.4)% BMI lossG1: 1.8 (2.6)G2: 0.6 (2.1)Mixed effects model medication effectPercent BMI loss F=10.57, p=0.008wk weightG1: NRG2: NRMean (SD) weight loss (kg)G1: 1.68 (2.69)G2: 0.43 (2.12)p=NR, stated as significant | NA | NA | NA |